Lotus Pharma Q3 revenue rises 27.5%
Lotus Pharma has posted a net income of $6.7m for the third quarter 2010, or $0.12 per diluted share, compared to net income of $5.39m, or $0.11 per
Summit Therapeutics’ partner Akeso has secured China’s National Medical Products Administration (NMPA) authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (NSCLC) patients.